The 2020 Menopausal Hormone Therapy Guidelines

참고문헌 (214)

1. Cobin RH, "American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on menopause-2017 update", Endocr Pract, 23, pp.869~880 (2017)
2. "The 2017 hormone therapy position statement of the North American Menopause Society", Menopause, 25, pp.1362~1387 (2018)
3. Jane FM, "A practitioner's toolkit for managing the menopause", Climacteric, 17, pp.564~579 (2014)
4. "Clinical Care Recommendations. Chapter 1-8"[URL]
5. Department of Reproductive Health, "Medical eligibility criteria for contraceptive use" (2010), World Health Organization Press
6. Blümel JE, "A scheme of combined oral contraceptives for women more than 40 years old", Menopause, 8, pp.286~289 (2001)
7. Kaunitz AM, "Clinical practice. Hormonal contraception in women of older reproductive age", N Engl J Med, 358, pp.1262~1270 (2008)
8. Santoro N, "Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women : a pilot study", Menopause, 22, pp.1301~1307 (2015)
9. Geiger PJ, "Effects of perimenopausal transdermal estradiol on selfreported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms", Menopause, 26, pp.1318~1323 (2019)
10. Gordon JL, "Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition : a randomized clinical trial", JAMA Psychiatry, 75, pp.149~157 (2018)
11. Marjoribanks J, "Long term hormone therapy for perimenopausal and postmenopausal women", Cochrane Database Syst Rev, (7), pp.CD004143~ (2012)
12. Huang KE, "Menopause perspectives and treatment of Asian women", Semin Reprod Med, 28, pp.396~403 (2010)
13. Hunter MS, "Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women : impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10, 418 British women aged 54-65", BJOG, 119, pp.40~50 (2012)
14. Mishra GD, "Health symptoms during midlife in relation to menopausal transition : British prospective cohort study", BMJ, 344, pp.e402~ (2012)
15. Hemminki E, "Variability of bothersome menopausal symptoms over time--a longitudinal analysis using the Estonian postmenopausal hormone therapy trial(EPHT)", BMC Womens Health, 12, pp.44~ (2012)
16. Akhila V, Pratapkumar, "A comparison of transdermal and oral HRT for menopausal symptom control", Int J Fertil Womens Med, 51, pp.64~69 (2006)
17. 염선경, "한국 여성에서 폐경증상 중 혈관운동증상에 대한 역학 조사", 대한폐경학회지, 18(3), pp.147~154 (2012), 대한폐경학회
18. Park HM, "The HRT awareness and acceptance in Korean postmenopausal women: results of Korean Gallup epidemiologic survey on menopause and HRT", J Korean Soc Menopause, 8, pp.3~18 (2002)
19. Heikkinen JE, "Optimizing continuous-combined hormone replacement therapy for postmenopausal women : a comparison of six different treatment regimens", Am J Obstet Gynecol, 182, pp.560~567 (2000)
20. Notelovitz M, "Initial 17beta-estradiol dose for treating vasomotor symptoms", Obstet Gynecol, 95, pp.726~731 (2000)
21. Panay N, "Ultra-low-dose estradiol and norethisterone acetate : effective menopausal symptom relief", Climacteric, 10, pp.120~131 (2007)
22. Baber RJ, "2016 IMS Recommendations on women's midlife health and menopause hormone therapy", Climacteric, 19, pp.109~150 (2016)
23. Birkhäuser MH, "Updated practical recommendations for hormone replacement therapy in the peri-and postmenopause", Climacteric, 11, pp.108~123 (2008)
24. Ettinger B, "Low-dosage esterified estrogens opposed by progestin at 6-month intervals", Obstet Gynecol, 98, pp.205~211 (2001)
25. Lindh-Astrand L, "Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy : a Swedish population-based study", Menopause, 16, pp.1213~1217 (2009)
26. Kim OM, "The climacteric symptoms and quality of life in climacteric women according to hormone replacement therapy", Korean J Women Health Nurs, 7, pp.642~656 (2001)
27. Cho HH, "Influences of hormone therapy to tissue mineral concentration and quality of life in menopausal women", J Korean Soc Menopause, 13, pp.209~216 (2007)
28. Kim JY, "Assessment about quality of life in menopausal women with hormone replacement therapy", Korean J Obstet Gynecol, 41, pp.2429~2435 (1998)
29. Westlund Tam L, "Does estrogen enhance the antidepressant effects of fluoxetine?", J Affect Disord, 77, pp.87~92 (2003)
30. Palacios S, "Update on management of genitourinary syndrome of menopause : a practical guide", Maturitas, 82, pp.308~313 (2015)
31. Nappi RE, "The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI", Climacteric, 15, pp.267~274 (2012)
32. Rahn DD, "Vaginal estrogen for genitourinary syndrome of menopause: a systematic review", Obstet Gynecol, 124, pp.1147~1156 (2014)
33. Lethaby A, "Local oestrogen for vaginal atrophy in postmenopausal women", Cochrane Database Syst Rev, 2016, pp.CD001500~ (2016)
34. "Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society", Menopause, 20, pp.888~902 (2013)
35. Constantine G, "Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy : results of a randomized, placebo-controlled trial", Climacteric, 18, pp.226~232 (2015)
36. Labrie F, "Efficacy of intravaginal dehydroepiandrosterone(DHEA)on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause", Menopause, 23, pp.243~256 (2016)
37. Sokol ER, "An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy", Menopause, 23, pp.1102~1107 (2016)
38. "FDA Warns against use of energy-based devices to perform vaginal 'rejuvenation' or vaginal cosmetic procedures: FDA safety communication" (2018)[URL]
39. Gordon C, "Rethinking the techno vagina : a case series of patient complications following vaginal laser treatment for atrophy", Menopause, 26, pp.423~427 (2019)
40. Long CY, "A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women", Fertil Steril, 85, pp.155~160 (2006)
41. Robinson D, "Oestrogens and overactive bladder", Neurourol Urodyn, 33, pp.1086~1091 (2014)
42. Matsubara S, "Estrogen levels influence beta-3-adrenoceptor-mediated relaxation of the female rat detrusor muscle", Urology, 59, pp.621~625 (2002)
43. Ismail SI, "Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women", Cochrane Database Syst Rev, (9), pp.CD007063~ (2010)
44. Grady D, "Postmenopausal hormones and incontinence : the Heart and Estrogen", Progestin Replacement Study, 2001, pp.97, 116~120
45. Hendrix SL, "Effects of estrogen with and without progestin on urinary incontinence", JAMA, 293, pp.935~948 (2005)
46. Cody JD, "Oestrogen therapy for urinary incontinence in post-menopausal women", Cochrane Database Syst Rev, 10, pp.CD001405~ (2012)
47. Dueñas-Garcia OF, "Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women", Female Pelvic Med Reconstr Surg, 22, pp.63~69 (2016)
48. Appa AA, "The impact of multimorbidity on sexual function in middleaged and older women : beyond the single disease perspective", J Sex Med, 11, pp.2744~2755 (2014)
49. Avis NE, "Longitudinal changes in sexual functioning as women transition through menopause : results from the Study of Women's Health across the Nation", Menopause, 16, pp.442~452 (2009)
50. Dennerstein L, "Are changes in sexual functioning during midlife due to aging or menopause", Fertil Steril, 76, pp.456~460 (2001)
51. Lonnèe-Hoffmann RA, "Sexual function in the late postmenopause : a decade of follow-up in a population-based cohort of Australian women", J Sex Med, 11, pp.2029~2038 (2014)
52. Erekson EA, "Oophorectomy : the debate between ovarian conservation and elective oophorectomy", Menopause, 20, pp.110~114 (2013)
53. Wierman ME, "Androgen therapy in women : a reappraisal : an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 99, pp.3489~3510 (2014)
54. Nappi RE, "Pharmacogenomics and sexuality: a vision", Climacteric, 16(Suppl 1), pp.25~30 (2013)
55. Nappi RE, "Advances in pharmacotherapy for treating female sexual dysfunction", Expert Opin Pharmacother, 16, pp.875~887 (2015)
56. Pines A, "Quality of life and the role of menopausal hormone therapy", Climacteric, 15, pp.213~216 (2012)
57. Nastri CO, "Hormone therapy for sexual function in perimenopausal and postmenopausal women", Cochrane Database Syst Rev, (6), pp.CD009672~ (2013)
58. Biglia N, "Tibolone in postmenopausal women : a review based on recent randomised controlled clinical trials", Gynecol Endocrinol, 26, pp.804~814 (2010)
59. Davis S, "Safety and efficacy of a testosterone metereddose transdermal spray for treating decreased sexual satisfaction in premenopausal women : a randomized trial", Ann Intern Med, 148, pp.569~577 (2008)
60. Goldstat R, "Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women", Menopause, 10, pp.390~398 (2003)
61. Fooladi E, "Testosterone improves antidepressant-emergent loss of libido in women : findings from a randomized, double-blind, placebocontrolled trial", J Sex Med, 11, pp.831~839 (2014)
62. Elraiyah T, "The benefits and harms of systemic dehydroepiandrosterone(DHEA)in postmenopausal women with normal adrenal function : a systematic review and meta-analysis", J Clin Endocrinol Metab, 99, pp.3536~3542 (2014)
63. Davis SR, "Testosterone for low libido in postmenopausal women not taking estrogen", N Engl J Med, 359, pp.2005~2017 (2008)
64. Berman JR, "Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status", Fertil Steril, 79, pp.925~931 (2003)
65. Raghunandan C, "A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women", J Sex Med, 7, pp.1284~1290 (2010)
66. Fernandes T, "Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women : a randomized controlled trial", J Sex Med, 11, pp.1262~1270 (2014)
67. Grossman DC, "Hormone therapy for the primary prevention of chronic conditions in postmenopausal women : US Preventive Services Task Force recommendation statement", JAMA, 318, pp.2224~2233 (2017)
68. Humphrey LL, "Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease", Ann Intern Med, 137, pp.273~284 (2002)
69. Hulley S, "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women", JAMA, 280, pp.605~613 (1998)
70. Grady D, "Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen", progestin Replacement Study follow-up (HERS II), 2002, pp.288, 49~57
71. Manson JE, "Estrogen plus progestin and the risk of coronary heart disease", N Engl J Med, 349, pp.523~534 (2003)
72. Hsia J, "Conjugated equine estrogens and coronary heart disease : the Women's Health Initiative", Arch Intern Med, 166, pp.357~365 (2006)
73. Rossouw JE, "Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause", JAMA, 297, pp.1465~1477 (2007)
74. Salpeter SR, "Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis", J Gen Intern Med, 21, pp.363~366 (2006)
75. Boardman HM, "Hormone therapy for preventing cardiovascular disease in post-menopausal women", Cochrane Database Syst Rev, (3), pp.CD002229~ (2015)
76. Harman SM, "Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women : a randomized trial", Ann Intern Med, 161, pp.249~260 (2014)
77. Schierbeck LL, "Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial", BMJ, 345, pp.e6409~ (2012)
78. Hodis HN, "Vascular effects of early versus late postmenopausal treatment with estradiol", N Engl J Med, 374, pp.1221~1231 (2016)
79. Manson JE, "Estrogen therapy and coronary-artery calcification", N Engl J Med, 356, pp.2591~2602 (2007)
80. Mikkola TS, "Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality", Menopause, 22, pp.976~983 (2015)
81. Manson JE, "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials", JAMA, 310, pp.1353~1368 (2013)
82. Renoux C, "Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study", BMJ, 340, pp.c2519~ (2010)
83. Jun Yup Kim, "Executive Summary of Stroke Statistics in Korea 2018: A Report from the Epidemiology Research Council of the Korean Stroke Society", 대한뇌졸중영문학회지, 21(1), pp.42~59 (2019), 대한뇌졸중학회[DOI]
84. Archer DF, "Estrogen and progestogen effect on venous thromboembolism in menopausal women", Climacteric, 15, pp.235~240 (2012)
85. Renoux C, "Hormone replacement therapy and the risk of venous thromboembolism : a population-based study", J Thromb Haemost, 8, pp.979~986 (2010)
86. Ridker PM, "Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening", JAMA, 277, pp.1305~1307 (1997)
87. Canonico M, "Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study", Circulation, 115, pp.840~845 (2007)
88. Canonico M, "Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women : systematic review and meta-analysis", BMJ, 336, pp.1227~1231 (2008)
89. Cushman M, "Estrogen plus progestin and risk of venous thrombosis", JAMA, 292, pp.1573~1580 (2004)
90. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, "The 2017 hormone therapy position statement of The North American Menopause Society", Menopause, 24, pp.728~753 (2017)
91. Miller J, "Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force", Ann Intern Med, 136, pp.680~690 (2002)
92. Suh JH, "A case of deep vein thromboembolism and Pulmonary embolism in postmenopausal hormone replacement therapy", J Korean Soc Menopause, 6, pp.162~167 (2000)
93. Anderson GL, "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled trial", JAMA, 291, pp.1701~1712 (2004)
94. Beral V, "Breast cancer and hormone-replacement therapy in the Million Women Study", Lancet, 362, pp.419~427 (2003)
95. Bush TL, "Hormone replacement therapy and breast cancer : a qualitative review", Obstet Gynecol, 98, pp.498~508 (2001)
96. Fournier A, "Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort", Int J Cancer, 114, pp.448~454 (2005)
97. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
98. Stahlberg C, "Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy", Br J Cancer, 91, pp.644~650 (2004)
99. Marsden J, "The risks and benefits of HRT before and after a breast cancer diagnosis", Post Reprod Health, 25, pp.33~37 (2019)
100. Chlebowski RT, "Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women : the Women's Health Initiative Randomized Trial", JAMA, 289, pp.3243~3253 (2003)
101. Anderson GL, "Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin", Maturitas, 55, pp.103~115 (2006)
102. Chlebowski RT, "Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women", JAMA, 304, pp.1684~1692 (2010)
103. Anderson GL, "Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy : extended follow-up of the Women's Health Initiative randomised placebo-controlled trial", Lancet Oncol, 13, pp.476~486 (2012)
104. LaCroix AZ, "Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy : a randomized controlled trial", JAMA, 305, pp.1305~1314 (2011)
105. Chen WY, "Unopposed estrogen therapy and the risk of invasive breast cancer", Arch Intern Med, 166, pp.1027~1032 (2006)
106. Fournier A, "Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort", Breast Cancer Res Treat, 145, pp.535~543 (2014)
107. Domchek SM, "Challenges to the development of new agents for molecularly defined patient subsets : lessons from BRCA1", 2-associated breast cancer, 2011, pp.29, 4224~4226
108. Eisen A, "Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers", J Natl Cancer Inst, 100, pp.1361~1367 (2008)
109. Gabriel CA, "Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy", Fam Cancer, 8, pp.23~28 (2009)
110. Rebbeck TR, "Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers : the PROSE Study Group", J Clin Oncol, 23, pp.7804~7810 (2005)
111. Holmberg L, "HABITS(hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison : trial stopped", Lancet, 363, pp.453~455 (2004)
112. Dixon JM, "Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer", J Clin Oncol, 26, pp.1671~1676 (2008)
113. "Breast cancer facts & figures 2018" (2018)[URL]
114. "United States cancer statistics: data visualizations" (2017)[URL]
115. "Cancer stat facts: female breast cancer" (2020)[URL]
117. Anderson GL, "Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures : the Women's Health Initiative randomized trial", JAMA, 290, pp.1739~1748 (2003)
118. Li D, "Postoperative hormone replacement therapy for epithelial ovarian cancer patients : a systematic review and meta-analysis", Gynecol Oncol, 139, pp.355~362 (2015)
119. "Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen", Progestin Interventions (PEPI) Trial, 1996, pp.275, 370~375
120. Biliatis I, "Safety of hormone replacement therapy in gynaecological cancer survivors", J Obstet Gynaecol, 32, pp.321~325 (2012)
121. Wei EK, "Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study", Am J Epidemiol, 170, pp.863~872 (2009)
122. Chlebowski RT, "Estrogen plus progestin and colorectal cancer in postmenopausal women", N Engl J Med, 350, pp.991~1004 (2004)
123. Delellis Henderson K, "Menopausal hormone therapy use and risk of invasive colon cancer : the California Teachers Study", Am J Epidemiol, 171, pp.415~425 (2010)
124. Mørch LS, "The influence of hormone therapies on colon and rectal cancer", Eur J Epidemiol, 31, pp.481~489 (2016)
125. Chlebowski RT, "Oestrogen plus progestin and lung cancer in postmenopausal women(Women's Health Initiative trial) : a post-hoc analysis of a randomised controlled trial", Lancet, 374, pp.1243~1251 (2009)
126. Shumaker SA, "Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women : Women's Health Initiative Memory Study", JAMA, 291, pp.2947~2958 (2004)
127. Shumaker SA, "Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women : the Women's Health Initiative Memory Study : a randomized controlled trial", JAMA, 289, pp.2651~2662 (2003)
128. Maki PM, "Hormone therapy, dementia, and cognition : the Women's Health Initiative 10 years on", Climacteric, 15, pp.256~262 (2012)
129. Resnick SM, "Postmenopausal hormone therapy and regional brain volumes : the WHIMS-MRI Study", Neurology, 72, pp.135~142 (2009)
130. Henderson VW, "Postmenopausal hormone therapy and Alzheimer's disease risk : interaction with age", J Neurol Neurosurg Psychiatry, 76, pp.103~105 (2005)
131. Zandi PP, "Hormone replacement therapy and incidence of Alzheimer disease in older women : the Cache County Study", JAMA, 288, pp.2123~2129 (2002)
132. Henderson VW, "Estrogen-containing hormone therapy and Alzheimer's disease risk : understanding discrepant inferences from observational and experimental research", Neuroscience, 138, pp.1031~1039 (2006)
133. Gleason CE, "Effects of hormone therapy on cognition and mood in recently postmenopausal women : findings from the randomized, controlled KEEPS-Cognitive and Affective Study", PLoS Med, 12, pp.e1001833~ (2015)
134. Whitmer RA, "Timing of hormone therapy and dementia : the critical window theory revisited", Ann Neurol, 69, pp.163~169 (2011)
135. Resnick SM, "Hormone therapy and risk of Alzheimer disease : a critical time", JAMA, 288, pp.2170~2172 (2002)
136. Greendale GA, "Effects of the menopause transition and hormone use on cognitive performance in midlife women", Neurology, 72, pp.1850~1857 (2009)
137. Espeland MA, "Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50to 55 years", JAMA Intern Med, 173, pp.1429~1436 (2013)
138. Brinton RD, "Investigative models for determining hormone therapy-induced outcomes in brain : evidence in support of a healthy cell bias of estrogen action", Ann N Y Acad Sci, 1052, pp.57~74 (2005)
139. Maki PM, "Critical window hypothesis of hormone therapy and cognition : a scientific update on clinical studies", Menopause, 20, pp.695~709 (2013)
140. Henderson VW, "Gonadal hormones and cognitive aging: a midlife perspective", Womens Health (Lond), 7, pp.81~93 (2011)
141. Rocca WA, "Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause", Neurology, 69, pp.1074~1083 (2007)
142. Sherwin BB, "Estrogen and", or androgen replacement therapy and cognitive functioning in surgically menopausal women, 1988, pp.13, 345~357
143. Asthana S, "Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease : results of a placebo-controlled, double-blind, pilot study", Psychoneuroendocrinology, 24, pp.657~677 (1999)
144. Ohkura T, "Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type", Endocr J, 41, pp.361~371 (1994)
145. Fillit H, "Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type", Psychoneuroendocrinology, 11, pp.337~345 (1986)
146. Mulnard RA, "Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study", JAMA, 283, pp.1007~1015 (2000)
147. Yoon BK, "Hormone replacement therapy in postmenopausal women with Alzheimer's disease : a randomized, prospective study", Fertil Steril, 79, pp.274~280 (2003)
148. The epidemiological survey of mental disorders in Korea 2011, "Seoul National University College of Medicine", Korean Ministry of Health and Welfare, ~ (2012)
149. Schmidt PJ, "A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women", Am J Psychiatry, 161, pp.2238~2244 (2004)
150. Freeman EW, "Associations of hormones and menopausal status with depressed mood in women with no history of depression", Arch Gen Psychiatry, 63, pp.375~382 (2006)
151. Sherwin BB, "Affective changes with estrogen and androgen replacement therapy in surgically menopausal women", J Affect Disord, 14, pp.177~187 (1988)
152. Ditkoff EC, "Estrogen improves psychological function in asymptomatic postmenopausal women", Obstet Gynecol, 78, pp.991~995 (1991)
153. Schmidt PJ, "Estrogen replacement in perimenopause-related depression : a preliminary report", Am J Obstet Gynecol, 183, pp.414~420 (2000)
154. Soares CN, "Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women : a double-blind, randomized, placebo-controlled trial", Arch Gen Psychiatry, 58, pp.529~534 (2001)
155. Rubinow DR, "Efficacy of estradiol in perimenopausal depression : so much promise and so few answers", Depress Anxiety, 32, pp.539~549 (2015)
156. Morrison MF, "Lack of efficacy of estradiol for depression in postmenopausal women : a randomized, controlled trial", Biol Psychiatry, 55, pp.406~412 (2004)
157. Yalamanchili V, "Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women : no interaction with estrogen and vitamin D receptor genotype polymorphisms", Menopause, 19, pp.697~703 (2012)
158. Schmidt PJ, "Effects of estradiol withdrawal on mood in women with past perimenopausal depression : a randomized clinical trial", JAMA Psychiatry, 72, pp.714~726 (2015)
159. North American Menopause Society, "The 2012 hormone therapy position statement of : the North American Menopause Society", Menopause, 19, pp.257~271 (2012)
160. Sherwin BB, "The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women", J Clin Endocrinol Metab, 72, pp.336~343 (1991)
161. "Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen", progestin interventions (PEPI)trial, 1996, pp.276, 1389~1396
162. Cauley JA, "Effects of estrogen plus progestin on risk of fracture and bone mineral density : the Women's Health Initiative randomized trial", JAMA, 290, pp.1729~1738 (2003)
163. Wells G, "Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women", Endocr Rev, 23, pp.529~539 (2002)
164. Lindsay R, "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women", JAMA, 287, pp.2668~2676 (2002)
165. Prestwood KM, "Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women : a randomized controlled trial", JAMA, 290, pp.1042~1048 (2003)
166. Barrett-Connor E, "Recency and duration of postmenopausal hormone therapy : effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment(NORA)study", Menopause, 10, pp.412~419 (2003)
167. Ha YC, "Current trends and future projections of hip fracture in South Korea using nationwide claims data", Osteoporos Int, 27, pp.2603~2609 (2016)
168. 전성욱, "기저 골밀도 및 이전 호르몬 치료 골반응에 따른 호르몬 치료 골반응", 대한폐경학회지, 18(1), pp.15~27 (2012), 대한폐경학회[DOI]
169. Hak Chul Jang, "How to Diagnose Sarcopenia in Korean Older Adults?", Annals of geriatric medicine and research, 22(2), pp.73~79 (2018), 대한노인병학회[DOI]
170. 김정희, "노인 인구에서 근감소증과 심혈관계 대사질환 위험인자와의 연관성 조사", Annals of geriatric medicine and research, 14(3), pp.121~130 (2010), 대한노인병학회
171. Kim TN, "Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study", Int J Obes (Lond), 33, pp.885~892 (2009)
172. 권형준, "Prevalence of Sarcopenia in the Korean Woman Based on the Korean National Health and Nutritional Examination Surveys", 대한골대사학회지, 23(1), pp.23~26 (2016), 대한골대사학회[DOI]
173. Hyoung Moo Park, "Current Status of Sarcopenia in Korea: A Focus on Korean Geripausal Women", Annals of geriatric medicine and research, 22(2), pp.52~61 (2018), 대한노인병학회[DOI]
174. 박형무, "Prevalence of Sarcopenia Adjusted Body Mass Index in the Korean Woman Based on the Korean National Health and Nutritional Examination Surveys", 대한골대사학회지, 23(4), pp.243~247 (2016), 대한골대사학회[DOI]
175. Brooke-Wavell K, "Effects of physical activity and menopausal hormone replacement therapy on postural stability in postmenopausal women--a cross-sectional study", Maturitas, 37, pp.167~172 (2001)
176. Chun SW, "Sarcopenia", pp.349~360 (2017), Koonja
177. Chen Z, "Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative", Am J Clin Nutr, 82, pp.651~656 (2005)
178. Choquette S, "Soy isoflavones and exercise to improve physical capacity in postmenopausal women", Climacteric, 16, pp.70~77 (2013)
179. "2018 Health insurance statistical yearbook" (2019)[URL]
180. Cirillo DJ, "Effect of estrogen therapy on gallbladder disease", JAMA, 293, pp.330~339 (2005)
181. Nelson HD, "Postmenopausal hormone replacement therapy", JAMA, 288, pp.872~881 (2002)
182. Panay N, "Management of premature ovarian failure", Best Pract Res Clin Obstet Gynaecol, 23, pp.129~140 (2009)
183. Landgren MB, "Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day", Maturitas, 50, pp.222~230 (2005)
184. Hammar ML, "Tibolone and low-dose continuous combined hormone treatment : vaginal bleeding pattern, efficacy and tolerability", BJOG, 114, pp.1522~1529 (2007)
185. Somunkiran A, "The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause : a randomized, cross-over study", Maturitas, 56, pp.61~68 (2007)
186. Kenemans P, "Tibolone: clinical recommendations and practical guidelines", Maturitas, 51, pp.21~28 (2005)
187. Sismondi P, "Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial", Maturitas, 70, pp.365~372 (2011)
188. Odabasi AR, "Effects of tibolone on abdominal subcutaneous fat, serum leptin levels, and anthropometric indices : a 6-month, prospective, randomized, placebo-controlled, double-blind study", Adv Ther, 23, pp.926~937 (2006)
189. Dedeoğlu EN, "Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women", Fertil Steril, 91, pp.425~431 (2009)
190. Meeuwsen IB, "Muscle strength and tibolone : a randomised, double-blind, placebocontrolled trial", BJOG, 109, pp.77~84 (2002)
191. Rymer J, "A study of the effect of tibolone on the vagina in postmenopausal women", Maturitas, 18, pp.127~133 (1994)
192. Nijland EA, "Tibolone and transdermal E2", NETA for the treatment of female sexual dysfunction in naturally menopausal women : results of a randomized active-controlled trial, 2008, pp.5, 646~656
193. Delmas PD, "Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women", Osteoporos Int, 19, pp.1153~1160 (2008)
194. Cummings SR, "The effects of tibolone in older postmenopausal women", N Engl J Med, 359, pp.697~708 (2008)
195. von Eckardstein A, "Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux", Clin Endocrinol (Oxf), 58, pp.49~58 (2003)
196. Kenemans P, "Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms : a double-blind, randomised, non-inferiority trial", Lancet Oncol, 10, pp.135~146 (2009)
197. de Villiers TJ, "Updated 2013International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health", Climacteric, 16, pp.316~337 (2013)
198. Archer DF, "Endometrial effects of tibolone", J Clin Endocrinol Metab, 92, pp.911~918 (2007)
199. Archer DF, "Tibolone histology of the endometrium and breast endpoints study : design of the trial and endometrial histology at baseline in postmenopausal women", Fertil Steril, 88, pp.866~878 (2007)
200. 김훈, "티볼론과 에스트라디올 기반 호르몬 치료가 골밀도와 혈중 지질에 미치는 영향", OSTEOPOROSIS, 10(1), pp.12~19 (2012), 대한골다공증학회[DOI]
201. Lee KB, "The safety of tibolone in epithelial ovarian cancer patients", Maturitas, 55, pp.156~161 (2006)
202. Lee KB, "Endometrial cancer patients and tibolone : a matched case-control study", Maturitas, 55, pp.264~269 (2006)
203. Lobo RA, "Evaluation of bazedoxifene", conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile, 2009, pp.92, 1025~1038
204. Mirkin S, "Effects of bazedoxifene", conjugated estrogens on endometrial safety and bone in postmenopausal women, 2013, pp.16, 338~346
205. Pinkerton JV, "Breast effects of bazedoxifene-conjugated estrogens : a randomized controlled trial", Obstet Gynecol, 121, pp.959~968 (2013)
206. Pickar JH, "Endometrial effects of a tissue selective estrogen complex containing bazedoxifene", conjugated estrogens as a menopausal therapy, 2009, pp.92, 1018~1024
207. Pinkerton JV, "Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene", conjugated estrogens : a randomized, controlled trial, 2009, pp.16, 1116~1124
208. Kagan R, "A randomized, placebo-and active-controlled trial of bazedoxifene", conjugated estrogens for treatment of moderate to severe vulvar, Menopause, pp.2010, 17[DOI]
209. Pinkerton JV, "Sleep parameters and health-related quality of life with bazedoxifene", conjugated estrogens : a randomized trial, 2014, pp.21, 252~259
210. Lindsay R, "Efficacy of tissue-selective estrogen complex of bazedoxifene", conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women, 2009, pp.92, 1045~1052
211. Thomas AM, "Disturbances of endometrial bleeding with hormone replacement therapy", Hum Reprod, 15(Suppl 3), pp.7~17 (2000)
212. Pinkerton JV, "Effects of bazedoxifene", conjugated estrogens on the endometrium and bone : a randomized trial, 2014, pp.99, E189~E198
213. Skouby SO, "Effects of conjugated estrogens", bazedoxifene on lipid and coagulation variables : a randomized placebo-and active-controlled trial, 2015, pp.22, 640~649
214. Stuenkel CA, "Treatment of symptoms of the menopause : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 100, pp.3975~4011 (2015)

관련 논문AI추천